Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00389064
Status:
COMPLETED
Last Update Posted:
2012-04-04
First Post:
2006-10-17
Brief Title:
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Multi-Centre Double-Blind Randomised Parallel-Group Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release Seroquel SR in the Treatment of Elderly Patients With Generalised Anxiety Disorder
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to evaluate whether treatment with SEROQUEL SR quetiapine fumarate sustained release SR for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder
PLEASE NOTE Seroquel SR and Seroquel extended releaseXR refer to the same formulation The SR designation was changed to XR after consultation with FDA
PLEASE NOTE Seroquel SR and Seroquel extended releaseXR refer to the same formulation The SR designation was changed to XR after consultation with FDA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT No 2006-001195-21 | None | None | None |